Publications by authors named "T Caldes"
Article Synopsis
- - The study aims to compare colorectal cancer (CRC) incidences between two groups: one group receiving mandatory colonoscopy surveillance (PLSD) and another group with retrospective data (IMRC) that did not have the same follow-up.
- - Results from the PLSD showed higher CRC rates in carriers of MMR gene variants, particularly for path_MLH1 and path_MSH2, compared to the IMRC cohort, challenging previous expectations about cancer rates in these groups.
- - The study concludes that while colonoscopy did reduce CRC incidences in paths_MPS2 carriers prior to age 50, it did not have the same effect for path_MLH1 and path_MSH2, suggesting the need for reevaluation of
Matrix metalloproteinase-11 (MMP11) is an enzyme with proteolytic activity against matrix and nonmatrix proteins. Although most MMPs are secreted as inactive proenzymes and are later activated extracellularly, MMP11 is activated intracellularly by furin within the constitutive secretory pathway. It is a key factor in physiological tissue remodeling and its alteration may play an important role in the progression of epithelial malignancies and other diseases.
View Article and Find Full Text PDFPurpose: Germline genetic testing for BRCA1 and BRCA2 variants has been a part of clinical practice for >2 decades. However, no studies have compared the cancer risks associated with missense pathogenic variants (PVs) with those associated with protein truncating (PTC) variants.
Methods: We collected 582 informative pedigrees segregating 1 of 28 missense PVs in BRCA1 and 153 pedigrees segregating 1 of 12 missense PVs in BRCA2.
Article Synopsis
- Researchers studied the impact of new polygenic risk scores (PRS) for breast and prostate cancer on male carriers of BRCA1 and BRCA2 gene mutations, analyzing data from 1,801 individuals across these two genes.
- The breast cancer PRS showed the strongest link to risk factors for BRCA1 and BRCA2 carriers, with specific odds ratios indicating increased risk associated with certain risk score variations.
- The findings highlight the need for further research to tailor cancer risk assessments for male BRCA mutation carriers, which could improve their clinical management and outcomes.